RNA-Based Therapeutics & Vaccines Market to Reach $2.32B by 2032

Driven by Rapid Expansion of mRNA Platform Applications, Emerging Modalities, and Scalable Manufacturing

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

The RNA-based Therapeutics and Vaccines Market is projected to reach approximately USD 2,320.54 million by 2032, expanding at a CAGR of 5.50% from 2025 to 2032. This growth is driven by increasing clinical success, rising investments in advanced biologics, and the expanding application of RNA platforms across multiple therapeutic areas, including infectious diseases, oncology, rare genetic disorders, and personalized medicine.

Why it matters

RNA technologies are rapidly emerging as one of the most transformative pillars of modern healthcare, enabling direct control over gene expression and protein production. The strong commercial validation of mRNA vaccines during the COVID-19 pandemic has accelerated research activity and industry confidence, opening new avenues for RNA-based therapeutics as a long-term growth engine for the biopharmaceutical sector.

The details

Emerging modalities such as self-amplifying and circular RNA, expanding oncology and rare-disease applications, and scalable manufacturing are creating high-growth investment avenues, supported by partnerships and faster regulatory pathways. The report offers detailed analysis by Product Type, RNA Technology, Indication, End User, and country & region, along with comprehensive competitive insights and market share of top players, helping stakeholders identify key revenue opportunities.

  • The RNA-based Therapeutics and Vaccines Market was valued at USD 1,285.10 million in 2024.
  • The market is projected to reach approximately USD 2,320.54 million by 2032.

The players

Acuitas Therapeutics, Inc.

A Canadian biotechnology company focused on the development of lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics.

Alnylam Pharmaceuticals, Inc.

A leading biopharmaceutical company pioneering the translation of RNA interference (RNAi) into a new class of innovative medicines.

Moderna, Inc.

An American biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines.

Pfizer Inc.

A multinational pharmaceutical and biotechnology corporation that has developed several mRNA-based COVID-19 vaccines.

Sanofi

A French multinational pharmaceutical company that has invested heavily in mRNA technology and RNA-based therapeutics.

Got photos? Submit your photos here. ›

What’s next

The outlook for RNA-based therapeutics and vaccines remains highly robust, supported by rapid platform diversification, manufacturing scale-up, and deeper clinical validation across multiple disease areas. The next phase of growth is being shaped by self-amplifying RNA (saRNA) and circular RNA technologies, which enable lower-dose, longer-lasting expression and improved stability, significantly enhancing commercial viability and global distribution potential.

The takeaway

RNA technologies are rapidly emerging as one of the most transformative pillars of modern healthcare, enabling direct control over gene expression and protein production. The strong commercial validation of mRNA vaccines during the COVID-19 pandemic has accelerated research activity and industry confidence, opening new avenues for RNA-based therapeutics as a long-term growth engine for the biopharmaceutical sector.